what are kras inhibitors?

Q: what are kras inhibitors?

In short KRAS inhibitors are medicines designed to block the KRAS protein, which helps cancer cells grow [1]. They are currently being studied in clinical trials for pancreatic cancer [6]. These drugs work best when combined with other treatments to stop the cancer from becoming resistant [2]. The details * Most pancreatic cancers have mutations in the KRAS gene, making it a key target for therapy [1]. * Older KRAS inhibitors, like sotorasib and adagrasib, only work on the G12C mutation, which is rare in pancreatic cancer (found in only 2%-3% of cases) [1]. * Newer drugs, such as MRTX1133 and HRS-4642, target the more common G12D mutation found in many patients [1], [4]. * Other new KRAS G12D inhibitors, including RNK08594 and GFH375, are also being tested in early clinical studies [6]. * Cancer cells often develop resistance to these drugs over time by changing their genetic makeup or cell state [2], [8]. * Combining KRAS inhibitors with chemotherapy or other drugs like nimotuzumab can help overcome this resistance and improve tumor control [2], [4]. What to know These treatments are still largely in the early stages of development and clinical trials [1], [6]. Resistance to these drugs is a major challenge because pancreatic cancer biology is complex [3]. The information provided here is for educational purposes only and does not replace professional medical advice.

Question

Accepted Answer

In short

KRAS inhibitors are medicines designed to block the KRAS protein, which helps cancer cells grow [1]. They are currently being studied in clinical trials for pancreatic cancer [6]. These drugs work best when combined with other treatments to stop the cancer from becoming resistant [2].

The details

* Most pancreatic cancers have mutations in the KRAS gene, making it a key target for therapy [1].

* Older KRAS inhibitors, like sotorasib and adagrasib, only work on the G12C mutation, which is rare in pancreatic cancer (found in only 2%-3% of cases) [1].

* Newer drugs, such as MRTX1133 and HRS-4642, target the more common G12D mutation found in many patients [1], [4].

* Other new KRAS G12D inhibitors, including RNK08594 and GFH375, are also being tested in early clinical studies [6].

* Cancer cells often develop resistance to these drugs over time by changing their genetic makeup or cell state [2], [8].

* Combining KRAS inhibitors with chemotherapy or other drugs like nimotuzumab can help overcome this resistance and improve tumor control [2], [4].

What to know

These treatments are still largely in the early stages of development and clinical trials [1], [6]. Resistance to these drugs is a major challenge because pancreatic cancer biology is complex [3]. The information provided here is for educational purposes only and does not replace professional medical advice.